1.41% -0.6309

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스

Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High at $47.75 - MarketBeat

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells $631,891.47 in Stock - Defense World

Principal Financial Group Inc. Sells 4,341 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Protagonist therapeutics CFO sells over $630k in company stock - Investing.com

HC Wainwright Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $50.00 - Defense World

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells $631,891.47 in Stock - MarketBeat

PTGX Shares Experience Surge in Value - Knox Daily

Protagonist Therapeutics director Waddill sells $360,000 in stock - Investing.com India

Protagonist Therapeutics director Waddill sells $360,000 in stock - Investing.com

Truist Securities Initiates Coverage of Protagonist Therapeutics (PTGX) with Buy Recommendation - MSN

HC Wainwright Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $50.00 - MarketBeat

TD Asset Management Inc Grows Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of “Buy” from Analysts - Defense World

TD Asset Management Inc Boosts Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Protagonist Therapeutics Inc (PTGX) expanding its growth trajectory ahead - SETE News

Objective long/short (PTGX) Report - Stock Traders Daily

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - AOL

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - Yahoo Finance

Great Lakes Advisors LLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Protagonist Therapeutics stock hits 52-week high at $43.79 By Investing.com - Investing.com Australia

Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at Truist Financial - Defense World

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High at $44.05 - MarketBeat

Protagonist Therapeutics stock hits 52-week high at $43.79 - Investing.com

Protagonist Therapeutics stock hits 52-week high at $43.79 By Investing.com - Investing.com Canada

Truist initiates coverage on Protagonist Therapeutics shares with Buy rating By Investing.com - Investing.com Canada

Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at Truist Financial - MarketBeat

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Simply Wall St

Candriam S.C.A. Sells 86,182 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Cannon Global Investment Management LLC Purchases New Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Check Out Protagonist Therapeutics Inc (PTGX)’s Trade Data Rather Than the Analysts’ Views - SETE News

Metric Analysis: Protagonist Therapeutics Inc (PTGX)’s Key Ratios in the Limelight - The Dwinnex

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 - StockTitan

Protagonist Therapeutics Inc [PTGX] Stock sold by Insider Waddill William D. for $0.32 million - Knox Daily

Protagonist Therapeutics stock hits 52-week high at $42.72 By Investing.com - Investing.com Australia

Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High at $43.31 - MarketBeat

Keeping an Eye on Protagonist Therapeutics Inc (PTGX) After Insider Trading Activity - Knox Daily

Protagonist Therapeutics stock hits 52-week high at $42.72 - Investing.com

Protagonist Therapeutics, Inc. announced that it expects to receive $18.04 million in funding. - Marketscreener.com

Protagonist Therapeutics, Inc. announced that it has received $18 million in funding from Pharmstandard International S.A., Johnson & Johnson InnovationJJDC, Inc., Lilly Ventures Management Company, LLC, Starfish Ventures Pty Ltd - Marketscreener.com

Taking the lead: Protagonist Therapeutics Inc (PTGX) - SETE News

SG Americas Securities LLC Buys Shares of 10,951 Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Hennion & Walsh Asset Management Inc. - Defense World

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Protagonist Therapeutics : Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera - Marketscreener.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of “Buy” by Analysts - Defense World

Long Term Trading Analysis for (PTGX) - Stock Traders Daily

Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences - Marketscreener.com

Protagonist Therapeutics : to Present at the BMO 2019 Prescription for Success Healthcare Conference - Marketscreener.com

California State Teachers Retirement System Sells 3,153 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

StockNews.com Upgrades Protagonist Therapeutics (NASDAQ:PTGX) to Buy - Defense World

PTGX Stock Sees Decline of Approximately -2.05% in Last Five Days - Knox Daily

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Forecasted to Earn FY2024 Earnings of $1.44 Per Share - Defense World

FY2024 EPS Estimates for Protagonist Therapeutics, Inc. Lowered by Analyst (NASDAQ:PTGX) - Defense World

FY2024 EPS Estimates for Protagonist Therapeutics, Inc. Lowered by Analyst (NASDAQ:PTGX) - MarketBeat

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Cut to $43.00 - Defense World

Protagonist Therapeutics (NASDAQ:PTGX) PT Raised to $40.00 - Defense World

Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at StockNews.com - MarketBeat

Is it possible to buy Protagonist Therapeutics Inc(PTGX) shares at a good price now? - US Post News

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Cut to $43.00 by Analysts at JMP Securities - MarketBeat

Protagonist Therapeutics (NASDAQ:PTGX) Issues Quarterly Earnings Results, Hits Expectations - MarketBeat

Protagonist Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News

Protagonist Therapeutics Inc (PTGX) Q2 2024 Earnings: EPS of -$0 - GuruFocus.com

PTGX (Protagonist Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update - AccessWire

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update - StockTitan

Polycythemia Vera Treatment Market Size 2034 | Protagonist - openPR

PTGX과 유사한 종목